ERBB2 and breast carcinoma: We next sought to extend the validation of the AS events to a panel of four breast cancer cell lines representative of different molecular subtypes of breast cancer i.e., T47D1 (luminal A), Hs578T (TNBC), MDA-MB-453 and SKBR3 (HER2).